Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Rochester researcher to continue MS study

A Rochester, New York, researcher will receive a $263,622 grant to continue his study of injury to brain cell connections (synapses) in multiple sclerosis (MS) through the American Brain Foundation (formerly the American Academy of Neurology Foundation) and the National Multiple Sclerosis Society Clinician-Scientist Development Award.

27 Apr 2012

HMS researcher receives $130,000 to conduct epilepsy study

A researcher from Beth Israel Deaconess Medical Center and Harvard Medical School is receiving $130,000 to conduct further research on memory dysfunction in epilepsy patients through the Susan S. Spencer Clinical Research Training Fellowship.

27 Apr 2012

UCSF researcher to study risk factors and consequences of stroke

A San Francisco researcher is receiving $130,000 for her research studying risk factors and consequences of stroke among different racial/ethnic groups through the AHA/ASA/ABF Lawrence M. Brass, MD, Stroke Research Postdoctoral Fellowship from the American Brain Foundation,(formerly the American Academy of Neurology Foundation), the American Heart Association and the American Stroke Association.

27 Apr 2012

UIC researcher to explore causes of myasthenia gravis

A University of Illinois at Chicago researcher is the recipient of a $240,000 research grant to further explore the causes of myasthenia gravis, a neurologic disease affecting muscles.

27 Apr 2012

Helpful roles of rank, toxic substances

Usually, we think of mold, feces, nitric oxide, hydrogen sulfide and rat poison as rank, toxic or both. But scientists funded by the National Institutes of Health are learning more about the helpful roles these substances can play.

26 Apr 2012

Active cognitive lifestyle lowers risk for dementia

The findings of a new study suggest that the protective effects of an active cognitive lifestyle arise through multiple biological pathways.

26 Apr 2012

Elan first quarter total revenue increases 17% to $288.4 million

Elan Corporation, plc, today reported its first quarter 2012 financial results.

26 Apr 2012

Non-coding RNA gives off biological signals during viral infection

Once considered unimportant "junk DNA," scientists have learned that non-coding RNA (ncRNA) - RNA molecules that do not translate into proteins - play a crucial role in cellular function. Mutations in ncRNA are associated with a number of conditions, such as cancer, autism, and Alzheimer's disease.

25 Apr 2012

U-M project to examine link between bipolar disorder and abnormalities in the circadian

A math professor at the University of Michigan will lead an international, $1 million project examining the links between bipolar disorder and abnormalities in the circadian, or daily, rhythms of a mammal's internal clock.

25 Apr 2012

AANF changes name to American Brain Foundation

The American Academy of Neurology Foundation is now the American Brain Foundation. The name change is part of an overall re-branding campaign as the organization repositions itself to become the world's leader in raising money for research to cure brain diseases, such as Alzheimer's disease, stroke, Parkinson's disease, autism, and epilepsy.

25 Apr 2012

LCP molecules can treat prion diseases

Toxic prions in the brain can be detected with self-illuminating polymers. The originators, at Linköping University in Sweden, has now shown that the same molecules can also render the prions harmless, and potentially cure fatal nerve-destroying illnesses.

25 Apr 2012

Neuron-killing pathology of AD requires presence of a-beta and elevated p-tau levels

According to a new study, the neuron-killing pathology of Alzheimer's disease (AD), which begins before clinical symptoms appear, requires the presence of both amyloid-beta (a-beta) plaque deposits and elevated levels of an altered protein called p-tau.

24 Apr 2012

Immunosignatures can yield reliable and highly stable diagnostic results

Identifying diseases at an early, presymptomatic stage may offer the best chance for establishing proper treatment and improving patient outcomes. A new technique known as immunosignaturing harnesses the human immune system as an early warning sentry-one acutely sensitive to changes in the body that may be harbingers of illness.

24 Apr 2012

Preventive treatments can reduce migraine attacks

Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.

24 Apr 2012

Exercise staves off dementia in older women: Study

Older women with first signs of memory decline might ward off full-blown dementia by engaging in routine strength training according to a new study. However supervised weight-lifting seems to be working better than aerobics-based activity programs, the study found. The study was conducted with researchers from the Department of Psychology and Division of Geriatric Medicine at UBC, and Department of Psychology at the University of Iowa.

24 Apr 2012

RVX-208 molecule increases apolipoprotein A-I production

Resverlogix Corp. today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production.

23 Apr 2012

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately $2 million in Series A financing, which includes both issuance of new convertible preferred shares and debt conversion.

23 Apr 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

LCIG improves quality of life, reduces symptoms of Parkinson's

A recent clinical trial conducted at Evergreen Healthcare shows that a new form of a common drug used to treat Parkinson's Disease greatly improves the quality of life for patients and reduces the affects of symptoms such as tremors, slowness, stiffness and difficulty walking.

21 Apr 2012

Penn researchers continue efforts to differentiate Alzheimer's from FTLD

Teasing out the exact type or types of dementia someone suffers from is no easy task; neurodegenerative brain diseases share common pathology and often co-occur. Researchers from the Perelman School of Medicine at the University of Pennsylvania are continuing efforts to differentiate diseases, such as Alzheimer's disease (AD) from frontotemporal lobar degeneration (FTLD), as FTLD is often clinically difficult to distinguish from atypical presentations of AD.

21 Apr 2012